Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2011-02-08FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)
FDA approved a supplemental application for ADCIRCA (tadalafil) submitted by United Therapeutics Corporation.
-
FDA approval · 2011-02-08FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for TYVASO (treprostinil) submitted by United Therapeutics Corporation. This action represents a…
-
FDA approval · 2011-02-08FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan), authorizing changes to its approved labeling.
-
FDA approval · 2010-11-19FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for REVATIO (sildenafil citrate) submitted by Pfizer Laboratories Division Pfizer Inc.
-
FDA approval · 2010-11-19FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Viatris Specialty LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2010-10-13FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, updating the labeling for the drug.
-
FDA approval · 2010-08-24FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc., updating the product’s labeling and/o…
-
FDA approval · 2010-08-23FDA Approved: VELETRI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for VELETRI (epoprostenol) submitted by Actelion Pharmaceuticals US, Inc. The product is used for tr…
-
FDA approval · 2010-02-19FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, resulting in a labeling update. Bosent…
-
FDA approval · 2010-01-08FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for REMODULIN (treprostinil) submitted by United Therapeutics Corporation.
-
FDA approval · 2009-11-18FDA Approved: REVATIO — Original Application (Viatris Specialty LLC)
The FDA approved Revatio (sildenafil citrate) via an original application by Viatris Specialty LLC for the treatment of pulmonary arterial h…
-
FDA approval · 2009-08-07FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) from Actelion Pharmaceuticals US, Inc., updating labeling and/or indications…
-
FDA approval · 2009-08-05FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences, Inc.
-
FDA approval · 2009-07-30FDA Approved: TYVASO — Original Application (United Therapeutics Corporation)
The FDA approved TYVASO (treprostinil) under its Original Application from United Therapeutics Corporation for the treatment of pulmonary ar…
-
FDA approval · 2009-07-01FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) submitted by Gilead Sciences.
-
FDA approval · 2009-05-29FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approves a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc., authorizing a change to its labeling.
-
FDA approval · 2009-05-22FDA Approved: ADCIRCA — Original Application (United Therapeutics Corporation)
FDA approved Adcirca (tadalafil) under the original application from United Therapeutics for the treatment of pulmonary arterial hypertensio…
-
FDA approval · 2009-05-07FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Pfizer Laboratories. The action relates to regulatory …
-
FDA approval · 2009-03-17FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) submitted by Actelion Pharmaceuticals US, Inc., resulting in an approval tha…
-
FDA approval · 2009-02-17FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
FDA approved a supplemental application for Revatio (sildenafil citrate) submitted by Pfizer Laboratories Division, Pfizer Inc. The approval…
-
FDA approval · 2008-09-12FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for REMODULIN (treprostinil) submitted by United Therapeutics Corporation.
-
FDA approval · 2008-06-27FDA Approved: VELETRI — Original Application (Actelion Pharmaceuticals US, Inc.)
FDA approved VELETRI (epoprostenol) from Actelion as an original application for treatment of pulmonary arterial hypertension.
-
FDA approval · 2008-02-25FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental NDA for sildenafil citrate filed by Mylan Pharmaceuticals Inc.
-
FDA approval · 2008-02-14FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc. The approval involves changes to the p…
-
FDA approval · 2008-02-04FDA Approved: REMODULIN — Supplemental Application (United Therapeutics Corporation)
FDA approved a Supplemental Application for REMODULIN (treprostinil) by United Therapeutics Corporation. This action relates to an update or…